logo
Book a meeting
OcuSciences

Ocu Sciences

Medical Devices, 2890 Carpenter Rd, Ann Arbor, Michigan, 48108, United States, 1-10 Employees

ocusciences.com

  • facebook
  • twitter
  • LinkedIn

Who is OCUSCIENCES

OcuSciences is a medical device company developing a rapid, unique and patented non-invasive ocular imaging technique called flavoprotein fluorescence (FPF). FPF is being developed to det...

Read More

lock icon Get Full Access
map
  • 2890 Carpenter Rd, Ann Arbor, Michigan, 48108, United States Headquarters: 2890 Carpenter Rd, Ann Arbor, Michigan, 48108, United States
  • 2008 Date Founded: 2008
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Medical Devices

SIC SIC Code: 8071 | NAICS Code: 621512 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from OCUSCIENCES

OcuSciences Org Chart and Mapping

Employees
Erich Heise

Erich Heise

Advisor

See Full Org Chart arrow
email-formate-icon
View Email Formats for OcuSciences
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding OcuSciences

Answer: OcuSciences's headquarters are located at 2890 Carpenter Rd, Ann Arbor, Michigan, 48108, United States

Answer: OcuSciences's official website is https://ocusciences.com

Answer: OcuSciences's revenue is $1 Million to $5 Million

Answer: OcuSciences's SIC: 8071

Answer: OcuSciences's NAICS: 621512

Answer: OcuSciences has 1-10 employees

Answer: OcuSciences is in Medical Devices

Answer: OcuSciences contact info: Phone number: Website: https://ocusciences.com

Answer: OcuSciences is a medical device company developing a rapid, unique and patented non-invasive ocular imaging technique called flavoprotein fluorescence (FPF). FPF is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, earlier than current clinical methods and before irreversible cell death becomes visible. The first device, the OcuMet Beacon, is currently being developed and validated at several top ophthalmic centers.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access